ZNRF3 and colorectal carcinoma: This abnormally high expression level enabled scientists at Genentech to develop the colorectal cancer (CRC)-specific degraders by adopting bi-specific antibodies.38 A series of antibodies with picomolar to nanomolar affinities against the ectodomains of RNF43 and ZNRF3 were obtained.